Artelo Biosciences (ARTL) Projected to Post Earnings on Monday

Artelo Biosciences (NASDAQ:ARTL) is expected to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter.

Artelo Biosciences (NASDAQ:ARTL) last posted its earnings results on Monday, March 3rd. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.43). On average, analysts expect Artelo Biosciences to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Artelo Biosciences Stock Performance

Shares of NASDAQ ARTL opened at $0.96 on Monday. The firm has a 50 day moving average price of $1.15 and a two-hundred day moving average price of $1.14. The stock has a market cap of $3.15 million, a P/E ratio of -0.33 and a beta of 1.06. Artelo Biosciences has a 52-week low of $0.91 and a 52-week high of $1.70.

Analyst Ratings Changes

ARTL has been the subject of several analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $6.00 target price on shares of Artelo Biosciences in a research report on Thursday, February 27th. LADENBURG THALM/SH SH upgraded Artelo Biosciences to a “strong-buy” rating in a research report on Wednesday, December 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Artelo Biosciences in a report on Tuesday, March 4th.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.